Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure

Warrasak, Sukhuma; Euswas, Ataya; Fukuda, Mark M.; Ittiverakul, Mali; Miller, R. Scott; Krudsood, Srivicha; Ohrt, Colin

doi:10.1007/s10792-018-1003-2

Cited by 12 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Induced ophthalmic changes are also known from other drugs, including the 4-aminoquinoline antimalarial CQ 46,47. Results of three following studies aimed to provide further evidence of the ophthalmic effects of TQ and did not find a clinically significant effect of TQ on ophthalmic function,19,41,45 even so a mild keratopathy was also observed with TQ when given for a short course (3 days) 41. One unpublished study (NCT02658435) submitted with the dossier to FDA was a phase I study designed to investigate ophthalmic safety of the 300 mg TQ dose for radical cure.…”

Section: Methodsmentioning

confidence: 99%

Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data

Hounkpatin¹,

Kreidenweiss²,

Held³

2019

IDR

View full text Add to dashboard Cite

Tafenoquine is an 8-aminoquinoline with activity against all human life cycle stages of Plasmodium vivax, including dormant liver stages – so called hypnozoites. Its long half-life of ~15 days is allowing for a single exposure regimen. It has been under development since 1980 and received approval by the US Food and Drug Administration in summer 2018 as an anti-relapse drug for P. vivax malaria in patients aged 16 years and older and for prophylaxis of malaria caused by any Plasmodium species in adults. Prior to tafenoquine administration, glucose-6-phosphate dehydrogenase (G6PD) deficiency needs to be excluded by testing. Individuals with a deficient G6PD activity are at risk of tafenoquine-induced hemolysis – as is the case for primaquine, the mainstay drug for P. vivax radical cure. A wealth of clinical studies have been conducted and are still ongoing to assess the safety, tolerability, and efficacy of tafenoquine. This review focuses on data emerging from the latest clinical trials on P. vivax radical cure with tafenoquine, the key studies for regulatory approval of tafenoquine, and elucidates the latest hypothesis on the mode of action.

show abstract

Section: Methodsmentioning

confidence: 99%

Clinical utility of tafenoquine in the prevention of relapse of Plasmodium vivax malaria: a review on the mode of action and emerging trial data

Hounkpatin¹,

Kreidenweiss²,

Held³

2019

IDR

View full text Add to dashboard Cite

show abstract

“…Reassuringly, no conclusive evidence of short-term ocular toxicity of clinical significance has been found in patients who received a single therapeutic dose of 300 mg of TQ, 77 nor in individuals who took 400 mg/day for three days. 78 Some minor and temporary ophthalmic changes were recorded, 77,78 as other authors have reported too. 73 In one study, no clinically significant ocular effects were detected at a dosing regimen of 200 mg of TQ daily for three consecutive days (this being a 600 mg loading dose), followed by 200 mg once weekly for 23 weeks.…”

Section: Eyesmentioning

confidence: 82%

Safety and Efficacy of Tafenoquine for Plasmodium vivax Malaria Prophylaxis and Radical Cure: Overview and Perspectives

Markus¹

2021

TCRM

View full text Add to dashboard Cite

This article is inter alia a brief, first-stop guide to possible adverse events (AEs) associated with tafenoquine (TQ) intake. Safety and efficacy findings for TQ in Plasmodium vivax malaria prophylaxis and radical cure are summarized and some of the latest TQ-related studies (published in 2020 and 2021) are highlighted. In addition, little-known biological and other matters concerning malaria parasites and 8-aminoquinoline (8-AQ) drug action are discussed and some correct terminology pertinent to malaria is explained.

show abstract

“…This fact means that the use of tafenoquine over chloroquine as an antimalarial drug is more favorable. 25…”

Section: Ophthalmological Effects Of Tafenoquine Usementioning

confidence: 99%

Use of Tafenoquine in Antimalarial Treatment: A Literature Review

Tefé-Silva,

França Barbosa,

Fernandes

et al. 2022

J App Pharm Sci Res

View full text Add to dashboard Cite

Besides the intensification of control measures, Plasmodium vivax poses a major challenge for malaria elimination efforts. This type of malaria parasite causes a persistent liver stage where the liver suffers the action of the hypnozoites, a form of the P. vivax that is very relevant at this stage of the infection and causes relapse of the disease and continued transmission. This literature review discusses an innovative treatment for malaria with tafenoquine (TQ), an 8-aminoquinoline synthetic primaquine analog that has been used in one dose for malaria relapse prevention and for prophylaxis due to its longer half-life, and its effects on the human body. Besides the use of tafenoquine, it was also necessary to discuss the Glucose-6-phosphate dehydrogenase (G6PD) deficiency, and the interaction of this enzyme with the 8-aminoquinolines, since both drugs may induce hemolytic anemia in patients with G6PD deficiency; therefore, the test to this deficiency is necessary before putting those patients under treatment with these drugs. The use of other drugs combined with tafenoquine was also reported. The drugs Primaquine, chloroquine, and other analogs, such as artemisinin and hybrids, were discussed in this article, along with their combined use and their greater or lesser help in the treatment.

show abstract

Comparative ophthalmic assessment of patients receiving tafenoquine or chloroquine/primaquine in a randomized clinical trial for Plasmodium vivax malaria radical cure

Cited by 12 publications

References 30 publications

<p>Clinical utility of tafenoquine in the prevention of relapse of <em>Plasmodium vivax</em> malaria: a review on the mode of action and emerging trial data</p>

<p>Clinical utility of tafenoquine in the prevention of relapse of <em>Plasmodium vivax</em> malaria: a review on the mode of action and emerging trial data</p>

Safety and Efficacy of Tafenoquine for Plasmodium vivax Malaria Prophylaxis and Radical Cure: Overview and Perspectives

Use of Tafenoquine in Antimalarial Treatment: A Literature Review

Contact Info

Product

Resources

About